

1 Two Distinct Regulatory Systems Control Pulcherrimin Biosynthesis in  
2 *Bacillus subtilis*

3

4 Nicolas L. Fernandez<sup>1</sup> and Lyle A. Simmons<sup>1\*</sup>

5

6 <sup>1</sup>Department of Molecular, Cellular, and Developmental Biology, University of Michigan,

7 Ann Arbor, MI 48109

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32 \*LAS: Department of Molecular, Cellular, and Developmental Biology, University of

33 Michigan, Ann Arbor, Michigan 48109-1055, United States. Phone: (734) 763-7142, Fax:

34 (734) 647-0884 E-mail: [lasimm@umich.edu](mailto:lasimm@umich.edu)

35 Short title: Transcriptional Regulation of Pulcherrimin Biosynthesis

36 **Keywords:** transcription factor, pulcherrimin, *Bacillus subtilis*, transition state

37

38 **Abstract**

39 Regulation of transcription is a fundamental process that allows bacteria to respond to  
40 external stimuli with appropriate timing and magnitude of response. In the soil bacterium  
41 *Bacillus subtilis*, transcriptional regulation is at the core of developmental processes  
42 needed for cell survival. Gene expression in cells transitioning from exponential phase to  
43 stationary phase is under the control of a group of transcription factors called transition  
44 state regulators (TSRs). TSRs influence numerous developmental processes including  
45 the decision between biofilm formation and motility, genetic competence, and sporulation,  
46 but the extent to which TSRs influence bacterial physiology remains to be fully elucidated.  
47 Here, we demonstrate two TSRs, ScoC and AbrB, along with the MerR-family  
48 transcription factor PchR negatively regulate production of the iron chelator pulcherrimin  
49 in *B. subtilis*. Genetic analysis of the relationship between the three transcription factors  
50 indicate that all are necessary to limit pulcherrimin production during exponential phase  
51 and influence the rate and total amount of pulcherrimin produced. Similarly, expression of  
52 the pulcherrimin biosynthesis gene *yvmC* was found to be under control of ScoC, AbrB,  
53 and PchR and correlated with the amount of pulcherrimin produced by each background.  
54 Lastly, our in vitro data indicate a weak direct role for ScoC in controlling pulcherrimin  
55 production along with AbrB and PchR. The layered regulation by two distinct regulatory  
56 systems underscores the important, and somewhat enigmatic, role for pulcherrimin in *B.*  
57 *subtilis* physiology.

58  
59  
60  
61

62 **Author Summary**

63 Regulation of gene expression is important for survival in ever changing environments. In  
64 the soil bacterium *Bacillus subtilis*, key developmental processes are controlled by  
65 overlapping networks of transcription factors, some of which are termed transition state  
66 regulators (TSRs). Despite decades of research, the scope of how TSRs influence *B.*  
67 *subtilis* physiology is still being uncovered. We found that three transcription factors, two  
68 of which are TSRs, converge to inhibit production of the iron-chelator pulcherrimin. Only  
69 when all three are missing is pulcherrimin production elevated. Finally, we demonstrate  
70 that expression of pulcherrimin biosynthesis genes occurs via direct and indirect  
71 regulation by the trio of transcription factors. Due to its iron chelating ability, pulcherrimin  
72 has been characterized as a modulator of niche development with antioxidant properties.  
73 Thus, our findings that TSRs control pulcherrimin, concurrently with other developmental  
74 phenotypes, provides new insight into how TSRs impact *B. subtilis* and its interaction with  
75 the environment.

76

## 77 **Introduction**

78           In the soil bacterium *Bacillus subtilis*, complex arrays of gene networks function  
79 together to precisely time the expression of gene products. A prime example is the series  
80 of decisions made as cells transition from exponential growth to stationary phase upon  
81 nutrient limitation [1]. This phase, termed the transition state, is where cells in the  
82 population use environmental cues to inform the next course of action to survive in the  
83 new environment, specifically whether to engage in competence, biofilm formation,  
84 motility, secondary metabolism, and/or acquisition of nutrients [1]. While there are many  
85 transcription factors controlling these processes, an important set among these are called  
86 transition state regulators (TSRs).

87           Originally defined in the context of sporulation, TSRs are regulators that inhibit  
88 expression of genes involved in developmental processes but do not result in a  
89 sporulation null mutation when deleted [2,3]. Notably, mutants in TSRs are still able to  
90 carry out post-exponential phenotypes, however the magnitude and timing of these  
91 phenotypes are disrupted [4]. ScoC and AbrB represent two well-studied TSRs in *B.*  
92 *subtilis*. ScoC is a MarR-family winged helix-turn-helix transcription factor first identified  
93 in hyper-protease mutants [5,6]. Microarray analysis between WT and *scoC* mutants  
94 identified 560 genes with differential gene expression involved in motility and genetic  
95 competence as well as protease production and peptide transport [7]. The smaller AbrB  
96 (10.8 kDa) is part of a large family of transcription factors with a beta-alpha-beta DNA  
97 binding N-terminal domain [8]. Mutants of *abrB*, like *scoC*, have pleiotropic effects with  
98 some overlap with ScoC [9,10]. ChiP-seq analyses of AbrB identified many binding sites  
99 with a bipartite TGGNA motif [11].

100 Pulcherrimin is a secreted iron chelating molecule that has been a topic of research  
101 in *Bacillus subtilis* and other microorganisms [12–16]. Pulcherrimin is synthesized by the  
102 1) cyclization of two tRNA-charged leucines to form cyclo-L(leucine-leucine) (cLL) and 2)  
103 oxidation to form water-soluble pulcherriminic acid (**Fig. 6A**). Pulcherriminic acid is then  
104 transported outside of the cell where it can bind to free ferric iron to form the water-  
105 insoluble pulcherrimin (**Fig. 6A**). Past work has demonstrated that pulcherrimin  
106 biosynthesis is under control of the MarR-family transcription factor PchR, which is found  
107 adjacent to genes involved in pulcherrimin biosynthesis and transport in *B. subtilis* [12,13].  
108 Interestingly, an AbrB binding site has been identified in the promoter for pulcherrimin  
109 biosynthesis genes, suggesting AbrB was involved in pulcherrimin biosynthesis [9,11].  
110 Whether other TSRs were involved in regulation pulcherrimin production is not known.

111 In this study, we provide evidence of multi-layered regulation of pulcherrimin  
112 biosynthesis by the TSRs ScoC and AbrB as well as the pulcherrimin regulator PchR. We  
113 explore the kinetics of pulcherrimin production throughout the transition state and found  
114 that ScoC, AbrB, and PchR control the timing, rate, and amount of pulcherrimin produced  
115 by modulating expression of the pulcherrimin biosynthetic gene cluster *yvmC-cypX*. We  
116 further establish the roles of PchR and AbrB in direct regulation of gene expression  
117 utilizing in vitro DNA binding assays and provide evidence that ScoC can bind directly to  
118 the *yvmC* promoter in vitro. Together our results suggest a model where pulcherrimin  
119 biosynthesis is regulated by nutrient levels during the transition from exponential phase  
120 to stationary phase in addition to input from PchR, linking stationary phase with  
121 extracellular iron sequestration.

## 122 **Methods**

### 123 **Bacterial Strains and Culturing**

124 A derivative of the wild-type strain 3610 *Bacillus subtilis* harboring an amino acid  
125 substitution in the competence inhibitor ComI (Q12I) was used as the background strain  
126 in these studies [17]. Gene replacements and deletions were constructed as described  
127 [18]. Gel purified gene-targeting antibiotic resistance cassettes and non-replicative  
128 plasmids (see Cloning for construction details) were used to transform *B. subtilis* by  
129 natural transformation. Briefly, single colonies of the strain of interest were inoculated  
130 into 1 mL LB supplemented with 3 mM MgSO<sub>4</sub> and grown to mid-log phase while shaking  
131 at 230 RPM at 37°C. The cultures were then back diluted 1:50 into 2 mL MD media (1X  
132 PC buffer [10X PC - 10.7 g K<sub>2</sub>HPO<sub>4</sub>, 6 g KH<sub>2</sub>PO<sub>4</sub>, 1.18 g trisodium citrate dehydrate,  
133 deionized water to 100 ml, filter sterilize], 2% glucose, 0.05 mg/mL tryptophan, 0.05  
134 mg/mL phenylalanine, 0.01 mg/mL ferric ammonium citrate, 2.5 mg/ml potassium  
135 aspartate, 3 mM MgSO<sub>4</sub>, water up to 2 mL) and grown for 3-5 hours, until early stationary  
136 phase. 10 µL of purified gene-targeting antibiotic resistance cassettes (~200-400 ng total)  
137 were added to 0.2 mL competent *B. subtilis*, were further incubated one hour, and plated  
138 on LB agar plate supplemented with either erythromycin (50 µg/mL), kanamycin (10  
139 µg/mL), chloramphenicol (5 µg/mL), and/or spectinomycin (100 µg/mL). Antibiotic  
140 resistance clones were rechecked on selection and insertions were verified by colony PCR  
141 using the US forward and DS reverse primers (See S Table 1). To remove the antibiotic  
142 resistance cassette, plasmid pDR224 was used to transform the appropriate strain with  
143 transformants selected for on LB supplemented with spectinomycin (100 µg/mL).  
144 Spectinomycin resistant clones were struck out on LB and incubated at the non-

145 permissive temperature of 42°C; this process was repeated twice. Clones were then  
146 rescreened for sensitivity of spectinomycin and the absence of the integrated antibiotic  
147 resistance cassette using PCR.

## 148 **Cloning**

149 To generate gene disruptions, oligos were designed to amplify upstream (US) and  
150 downstream (DS) of the gene of interest with appropriate overhangs to fuse either an  
151 erythromycin or kanamycin resistance cassette (AbR) flanked by CRE recombinase  
152 recognition sites [18]. Oligonucleotides were designed using NEBuilder (NEB) with the  
153 default parameters except minimum overlap length was changed from 20 nucleotides to  
154 30 nucleotides. Q5 polymerase (NEB) was used to amplify the appropriate PCR  
155 amplicon. All amplicons were gel extracted prior to assembly reactions (Qiagen). US, DS,  
156 and AbR fragments were assembled by splice by overlap extension (SOE) PCR (adapted  
157 from [19]). First, 0.5 pmol each of the US, DS, and AbR amplicons were mixed with 18  
158  $\mu\text{L}$  Q5 5X buffer, 0.25 mM dNTPs, and water up to 89  $\mu\text{L}$ . 1  $\mu\text{L}$  Q5 (2U) was added, and  
159 PCR was carried out with the following parameters: 1 cycle of 98°C – 10s, 10 cycles of  
160 98°C – 10s, 55°C – 30s, 72°C – 2 minutes, 1 cycle of 72°C – 10 minutes. After completion  
161 of the PCR, 5  $\mu\text{L}$  of US forward primer and 5  $\mu\text{L}$  of the DS reverse primer were added and  
162 PCR was set under the following conditions: 1 cycle of 98°C – 2 minutes, 15 cycles of  
163 98°C – 10s, 55°C – 30s, 72°C – 3 minutes, 1 cycle of 72°C – 10 minutes. Following PCR,  
164 spliced amplicons were analyzed on a gel and 10  $\mu\text{L}$  used directly for transformation into  
165 competent *B. subtilis*.

166 Vectors for protein purification (pNF039, pNF040, and pTMN007) and homologous  
167 recombination (pNF038) in *B. subtilis* were constructed using Gibson Assembly (NEB)

168 following the manufacturer's protocol. Protein expression vectors were used to transform  
169 *E. coli* DH5alpha and homologous recombination vectors were used to transform *E. coli*  
170 MC1061 and clones were verified via sanger sequencing (Azenta) or whole plasmid  
171 sequencing (Eurofins). All primers and assembly methods are included in S Table 1. To  
172 generate a *pyvmC*-GFP transcriptional fusion (pNF047), plasmid pYFP-STAR was  
173 amplified with the primer pair oNLF554-oNLF555 and gel extracted. The ORF for sfGFP  
174 was amplified from plasmid pDR110-GFP(Sp) using the primer pair oLVG035A-  
175 oLVG035B and gel extracted. The *pyvmC* locus was amplified in two fragments: 1)  
176 oNLF524-525 and 2) oNLF526-527. The resulting fragments were then assembled by  
177 Gibson Assembly (NEB), transformed into MC1061 *E. coli* cells by heat shock, and  
178 transformants were selected for by plating on LB Amp plates. The assembled plasmid  
179 consisted of the *pyvmC* promoter lacking 17 nucleotides upstream of the ATG start codon  
180 of *yvmC*, deleting the native ribosome binding site which can contribute to spurious  
181 translation and high GFP background [20].

## 182 **Media**

183 WT and derived *B. subtilis* strains were either grown in Luria broth or Tris-Spizizen salts  
184 (TSS) [Reagents added in order: 50 mM Tris pH 7.5, 136  $\mu$ M trisodium citrate dihydrate,  
185 water up to final volume, 2.5 mM dibasic potassium phosphate, 811  $\mu$ M MgSO<sub>4</sub>, 1X FeCl<sub>3</sub>  
186 from a 100X stock solution [150  $\mu$ M FeCl<sub>3</sub>, 0.1 g trisodium citrate dihydrate, 100 mL  
187 deionized water, filter sterilized], 0.5% glucose [25% stock solution, filter sterilized], and  
188 0.2% ammonium chloride [20% stock solution, filter sterilized]. For liquid TSS, all  
189 components were mixed, filter sterilized, stored in the dark, and used within a week. For  
190 TSS agar plates, all reagents, except the 1X FeCl<sub>3</sub> solution, glucose, and ammonium



191 chloride, were mixed with agar at 1.5% w/v and autoclaved. After the agar solution cooled  
192 to approximately 55°C, filter sterilized FeCl<sub>3</sub>, glucose, and ammonium chloride were  
193 added, approximately 20-25 mL were added to sterile petri plates, and plates were  
194 allowed to dry overnight. TSS agar plates were stored at 4°C and were used within 6  
195 months.

### 196 **Spot plating and liquid culture imaging**

197 One day prior to the spotting, TSS plates with varying concentrations of FeCl<sub>3</sub> (final  
198 concentrations: 0.15, 1.5, 15, and 150 μM FeCl<sub>3</sub>) were poured and dried overnight at  
199 room temperature. Spots for Fig. 1 were on TSS plates supplemented with 150 μM FeCl<sub>3</sub>.  
200 Strains were inoculated from frozen stocks into 1 mL TSS media and grown overnight at  
201 37°C while shaking at 250 RPM. The next day, the turbidity of each culture was measured  
202 and adjusted to an OD<sub>600</sub> of 1.0 in fresh TSS media. 10 μL of each culture were spotted  
203 15 mm apart on the same TSS plate and incubated for 24hr at 30°C. The next day, plates  
204 were imaged using an imaging box [21] and an iPhone 7 running iOS 15.7.5. Images  
205 were cropped and arranged using Adobe Photoshop and Illustrator. Each experiment  
206 included two technical spotting replicates and was repeated at least twice on separate  
207 days. For liquid cultures, 2 mL overnights were started from frozen stocks in TSS media  
208 and grown overnight at 37°C while shaking at 250 RPM. Overnight cultures were diluted  
209 to a starting OD<sub>600</sub> of 0.05 in 40 mL TSS in 125 mL flasks and grown for 20-24 hours at  
210 37°C while shaking at 250 RPM. Images of the flasks were taken as stated above.

## 211 **LC/MS for cyclo-dileucine measurement**

212 WT and *yvmC::erm* were struck out onto TSS plates from frozen stocks and grown  
213 overnight at 37°C for 16 hours. The next day, the strains were washed from the plate into  
214 fresh TSS and the resulting culture was used to inoculate 16 mL TSS in 50 mL flask at a  
215 starting OD<sub>600</sub> of 0.050. Cultures were grown for 6 hours while shaking at 250 RPM at  
216 37°C. After six hours (OD<sub>600</sub> ~ 1.0), 15 mL of culture was collected by centrifugation in a  
217 15-mL falcon tube (3 minutes, 4200xg) and the resulting pellets were resuspended in 200  
218 µL cold extraction buffer (acetonitrile:methanol:water, 40:40:20, [22]). The resulting  
219 cellular mixture was centrifuged in a microcentrifuge (30s, 15,000 x g) and the  
220 supernatant containing the extracted metabolites were moved to a new 1.5 mL  
221 microcentrifuge tube and frozen at -80C. Samples were sent to the Michigan State  
222 University Research Technology Support Facility for LC-MS analysis of cyclo-dileucine.  
223 Two hundred microliter of the extract was evaporated to dryness using a SpeedVac and  
224 resuspended with an equal volume of methanol: water, 1:9 (v/v). Ten microliter of the  
225 sample was injected onto an Acquity Premier HSS T3 column (1.8 µm, 2.1 x 100 mm,  
226 Waters, Milford, MA) and separated using a 10 min gradient as follows: 0 to 1 min were  
227 100% mobile phase A (0.1% formic acid in water) and 0% mobile phase B (acetonitrile);  
228 linear ramp to 99% B at 6 min, hold at 99% B until 8 min, return to 0% B at 8.01 min and  
229 hold at 0% B until 10 min. The column was held at 40°C and the flow rate was 0.3 mL/min.  
230 The mass spectrometer (Xevo G2-XS QToF, Waters, Milford, MA) was equipped with an  
231 electrospray ionization source and operated in positive-ion and sensitivity mode. Source  
232 parameters were as follows: capillary voltage 3000 V, cone voltage 30V, desolvation  
233 temperature 350 °C, source temperature 100 °C, cone gas flow 40 L/hr, and desolvation

234 gas flow 600 L/Hr. Mass spectrum acquisition was performed in positive ion mode with a  
235 range of  $m/z$  50 to 1500 with the target enhancement option tuned for  $m/z$  227. A  
236 calibration curve was made using cyclo-dileucine standard (Santa Cruz Biotechnology).  
237 The peak area for cyclo-dileucine was integrated based on the extracted ion  
238 chromatogram of  $m/z$  227.18 with an absolute window of 0.05 Da. Peak processing was  
239 performed using the Targetlynx tool in the Waters Masslynx software.

#### 240 **Pulcherrimin Isolation and Measurement**

241 Strains of interest were struck out on TSS agar plates from frozen stocks and incubated  
242 overnight (16-20 hours) at 37°C. The next day, cells were collected by adding 1 mL fresh  
243 TSS media to the plates and gently swirling to remove bacteria adhered to the agar. The  
244 resulting bacterial suspension was then moved to microcentrifuge tubes, the  $OD_{600}$   
245 recorded, and diluted to a starting  $OD_{600}$  of 0.05 in 40 mL TSS media in 125 mL round  
246 bottom flasks. At the time indicated, 1.5 mL of culture was aliquoted into a microcentrifuge  
247 tube. 0.1 mL were used for  $OD_{600}$  measurement while the remaining cells were collected  
248 by centrifugation (10,000 x g, 30s). The supernatant was removed and the cell pellet and  
249 insoluble pulcherrimin were resuspended in 0.1 mL 2M NaOH by pipetting the solution  
250 until completely resuspended. The samples were then centrifuged again (10,000 x g, 1  
251 minute) and the supernatant were moved to clean wells in a 96-well plate and absorbance  
252 at 410 nm was measured using a Tecan M200 plate reader.

253 To determine the time of entry into stationary phase, the R package growthrates  
254 was used to fit a linear growth model for every strain and replicate [23]. The time in which  
255 the growth data deviated from exponential growth was used as time 0 for Fig. 2. The  
256 `grow_gompertz3` function was used to model the change in absorbance at 410 nm over

257 time using the growthrates package [23]. Each strain and replicate ( $n = 3$ ) were modeled  
258 individually and the resulting parameters (maximum growth rate [ $\mu_{max}$ ] and carrying  
259 capacity (abs. 410 nm) [K]) were summarized by taking the average and standard  
260 deviation plotted in Fig. 1B. For the production start time, curves were analyzed manually  
261 to determine when the predicted  $A_{410}$  from the mutant strain deviated from the predicted  
262  $A_{410}$  value from the WT background during exponential phase. For duration of  
263 pulcherrimin production, the x-axis distance between the beginning of the exponential  
264 phase of pulcherrimin production and the start of the stationary phase of pulcherrimin  
265 production were measured manually.

## 266 **Epistasis Analysis**

267 Epistasis of double mutants were determined by applying the multiplicative model of  
268 epistasis, which states a series of gene deletions are epistatic if the sums of the single  
269 mutant phenotype (expected) are different than the phenotype of the double mutant  
270 (observed) [24]. Values greater than zero indicate positive epistasis while values less than  
271 zero indicate negative epistasis.

## 272 **Fluorescence Reporter Assay**

273 WT and isogenic mutants harboring the *pyvmC*-GFP transcriptional fusion at the *amyE*  
274 loci were struck out on TSS agar plates and grown overnight for ~ 16 hours at 37°C. The  
275 next day, the strains were plate washed into 1 mL TSS media and the  $OD_{600}$  was  
276 recorded. 40 mL TSS in 125 mL Erlenmeyer flasks were inoculated with the plate washed  
277 cells at a starting  $OD_{600}$  of 0.050. The cultures were incubated at 37°C while shaking at  
278 250 RPM until the cultures reached mid-exponential phase. Fluorescence was measured

279 from a 1 mL sample using an Attune NxT Acoustic Focusing Cytometer (ThermoFisher  
280 Scientific) using the following settings: Flow rate, 25  $\mu$ l/min; FSC voltage, 200; SSC  
281 voltage, 250; BL1 voltage, 250 [25].

## 282 **Protein Purification**

283 ScoC purification was carried out as previously described with some minor amendments  
284 [25]. Plasmid pTMN007 harboring ScoC in a T7 expression vector pE-SUMO was use to  
285 transform BL21-DE3 *E. coli* and plated on LB supplemented with kanamycin (25  $\mu$ g/mL).  
286 The next day, a single colony was inoculated into 1 mL LB Kan<sub>25</sub>, grown to mid-  
287 exponential phase at 37°C while shaking at 230 RPM, diluted 1:5 in 5 mL LB Kan<sub>25</sub>, and  
288 grown overnight at 37°C while shaking at 37°C. After overnight growth, the culture was  
289 diluted to a starting OD<sub>600</sub> of 0.05 in 400 mL LB Kan<sub>25</sub> at 37°C shaking at 230 RPM and  
290 grown until the OD<sub>600</sub> reached between 0.7, after which 1 mM final concentration of  
291 Isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG) was added to induce protein expression  
292 for three hours at 37°C. After induction, cells were collected by centrifugation (5 minutes  
293 at 7,500 RPM using SLA-1500 rotor in a Sorvall RC 5B plus centrifuge) and cell pellets  
294 were stored at -20C until use. Cell pellets were thawed at room temperature and  
295 resuspended in 40 mL lysis buffer (50 mM Tris pH 8, 300 mM NaCl, 10% sucrose, 10 mM  
296 imidazole, and 1 EDTA-free protease inhibitor tablet added the day of purification  
297 (Roche)). The cell solution was moved to a beaker in an ice-water bath and was sonicated  
298 (15s ON, 25s OFF, 24 cycles, 50% amplitude, Fisher Scientific Model 505 Sonic  
299 Dismembrator). The lysate was cleared by centrifugation (10 minutes, 12,000 RPM,  
300 using an SS-34 rotor in a Sorvall RC 5B plus centrifuge). The clarified lysate was loaded  
301 onto a 3 mL Ni-NTA column pre-equilibrated with lysis buffer and the flow through was

302 discarded. The column was washed three times with 20 mL wash buffer (50 mM Tris pH  
303 8, 2M NaCl, 25 mM imidazole, and 5% glycerol) and ScoC-SUMO-His was eluted with 15  
304 mL elution buffer (50 mM Tris pH 8, 150 mM NaCl, 200 mM imidazole). The protein  
305 solution was dialyzed at 4°C into dialysis buffer (50 mM Tris pH 8, 150 mM NaCl, 5%  
306 glycerol). The next day, DTT (1 mM) and SUMO Ulp1 protease were added, the solution  
307 was incubated at room temperature for 2 hours and dialyzed into dialysis buffer overnight  
308 at 4°C. Following dialysis, SUMO-free ScoC was purified by loading the solution onto 3  
309 mL of pre-equilibrated Ni-NTA resin by collecting the flow through. SUMO-free ScoC  
310 fractions were determined via SDS-PAGE, pooled, quantified by the Bradford assay,  
311 diluted with glycerol for a final concentration of 25%, and stored at -80°C.

312 Expression vectors for PchR and AbrB were constructed similar to ScoC. Growth  
313 of BL21 *E. coli* harboring PchR was identical to ScoC. Growth of BL21 *E. coli* harboring  
314 AbrB had the following changes. First, 1 mL LB Kan was inoculated with a single colony  
315 of *E. coli* harboring the AbrB expression vector and grown for 6 hours at 37°C, shaking at  
316 200 RPM. The 1 mL culture was diluted 1:10 in 9 mL LB Kan in a 125 mL flask and grown  
317 overnight at 37°C while shaking at 200 RPM. The next day, the culture was used to  
318 inoculate 400 mL of LB Kan at a starting OD<sub>600</sub> of 0.1 and grown at 30°C until the OD<sub>600</sub>  
319 reached between 0.6 and 0.7, at which point IPTG was added at a final concentration of  
320 1 mM and the culture was moved to 16°C with shaking at 160 RPM for 16 hours. For  
321 purification, slight modifications to the lysis buffer and elution buffers were made. Frozen  
322 pellets of PchR-SUMO and AbrB-SUMO were resuspended in 40 mL lysis buffer (50 mM  
323 Tris pH 8, 500 mM NaCl, 10% glycerol, 20 mM imidazole, supplemented with 1 EDTA-  
324 free protease inhibitor tablet), lysed by sonication, and the lysate cleared by

325 centrifugation. Clarified lysate was applied to 3 mL Ni-NTA resin columns, the columns  
326 were washed with 60 mL lysis buffer, and proteins were eluted by step elution using 5 mL  
327 each of increasing imidazole concentrations (elution buffer: 50 mM Tris pH 8, 500 mM  
328 NaCl, 10% glycerol, imidazole at 50, 100, 200, and 350 mM). Elution fractions were  
329 assayed for relative protein concentration by the Bradford assay (BioRad) and fractions  
330 containing protein were electrophoresed on SDS-PAGE to ensure proper expression and  
331 purification. Removal of the SUMO tag and purification of SUMO-free protein was carried  
332 out as described above. SUMO-free AbrB required an additional anion exchange  
333 purification step using a HiTrap qFF (Cytivia 17515601) anion exchange column attached  
334 to an AKTA FPLC. The column was equilibrated with 10% Q Buffer B (50 mM Tris, 5%  
335 glycerol, and 500 mM NaCl). Sumo-free AbrB was diluted to 50 mM NaCl in Q Buffer A  
336 and loaded into the column. Protein fractions (2 mL) were collected as the system  
337 increased the percentage of Q Buffer B while monitoring A260 readings. High A260 peaks  
338 were measured for AbrB on SDS-PAGE and correct fractions were pooled, dialyzed,  
339 concentrated by dialysis, mixed with glycerol at 25% final concentration, and stored at -  
340 80C.

#### 341 **Electrophoretic Mobility Shift Assays**

342 5' IRDye<sup>®</sup> 700-labeled probes of the *yvmC* promoter (-244 to +9 relative to the ATG start  
343 codon) were generated by PCR using the primer pair oNLF433-oNLF387 using pNF035  
344 as a template. PCR products were purified by gel extract and quantified by nanodrop. To  
345 generate the *PyvmC* $\Delta$ 59 probe, two PCR reactions were carried out with primer pairs  
346 oLVG025A-oNLF467 and oNLF468-oNLF387. The two PCR products were gel extracted  
347 and fused together by SOE PCR (see Cloning). The fragment was then used as template



348 for PCR with primer pairs oNLF433-oNLF387, resulting in a 5' IRDye<sup>®</sup> 700 labeled DNA  
349 fragment lacking 59-bp. Binding reactions were assembled by first generating a binding  
350 solution: 1X binding buffer (5X binding buffer: 250 mM Tris pH 8, 5 mM EDTA, 150 mM  
351 KCl, 10 mM MgCl<sub>2</sub>, 12.5 mM DTT, 1.25% Tween 20, and 2.5 mg/mL BSA), 1X DNA probe  
352 (10X probe, 100 nM), 1 μL protein of interest (5X stock concentration), and water up to 5  
353 μL. The binding reactions were incubated for 30 minutes at 37°C. When indicated, 1 μL  
354 of 1X heparin (6X heparin: 0.06 mg/mL) was added to each reaction after incubation and  
355 3 μL were loaded into the wells of a 15-well 6% polyacrylamide gel and ran for 60 minutes  
356 at 150V at room temperature. After gel electrophoresis, the gels were left in the glass  
357 plates and imaged using an Odyssey xCI imager (1.5 mm offset height, 84 μm resolution).  
358 The resulting images were adjusted in Fiji [26] and cropped and annotated in Adobe  
359 Illustrator<sup>®</sup>. EMSA experiments were carried out at least three times with separate  
360 aliquots for each protein.

### 361 **Fluorescent DNase I and Differential Peak Height Analysis**

362 5' FAM-labeled probes were generated by PCR using the primer pair oNLF432-oNLF387  
363 using pNF035 as a template. PCR products were purified by gel extraction and quantified  
364 by nanodrop. Binding reactions were assembled and carried out identically to EMSA  
365 experiments. After incubation, 1 μL 0.6 mg/mL heparin, and 0.79 μL of 10X DNase I buffer  
366 (Invitrogen) were added to the binding reactions followed by 1.2 μL of diluted DNase I  
367 (0.625 U total, Invitrogen) and reactions were incubated at room temperature for 5  
368 minutes. After 5 minutes, reactions were heated to 72°C for 10 minutes and DNA was  
369 immediately purified by phenol-chloroform extraction and ethanol precipitation.  
370 Reactions were resuspended in 10 μL water (company) and submitted for fragment



371 analysis by Azenta®. The resulting .fa files were imported into R and the data aligned to  
372 the LIZ500 reference standards using the *storing.indxs* and *overview* functions from the R  
373 package Fragman [27]. To analyze differences between peak heights, the R function  
374 findPeaks was used to extract local maxima in the sequential peak height data [28].  
375 Differential peak height analysis was carried out as described in [29]. Briefly, the raw  
376 signal for each sample was normalized by dividing by the sum of all signals. Then, the  
377 normalized signal for the sample incubated with protein was subtracted from the signal  
378 incubated without protein, producing the differential peak height. DNase I protection  
379 produces negative values while DNase I hypersensitivity produces positive values.  
380 DNase I footprinting and differential peak height analysis were carried out at least twice  
381 with separate protein aliquots.

382

## 383 **Results**

### 384 **ScoC Negatively Regulates Pulcherrimin Production**

385         The TSR ScoC represses gene expression during exponential phase [5,10,30]. As  
386 nutrients become limiting, the effect of ScoC repression is lessened by downregulation of  
387 *scoC* expression and competition between other DNA binding proteins [10,30,31]. Our  
388 lab has identified ScoC as a methylation-responding transcription factor at a promoter of  
389 a gene not involved in protease production, thus we were interested in further  
390 characterizing the role of ScoC as a TSR in *B. subtilis* [25]. When culturing our WT strain  
391 (DK1042) to late stationary phase cultures appear grey in liquid minimal media (Tris-  
392 Spizizen Salts, TSS) and appear red on TSS agar (**Fig. 1**). An isogenic *scoC* disruption  
393 mutant (*scoC::erm*), interestingly, appears pink in liquid TSS and has a more intense  
394 coloring when grown on solid TSS plates compared to WT (**Fig. 1**). The red phenotype  
395 was 1) dependent on the amount of FeCl<sub>3</sub>, 2) not present on standard LB plates, and 3)  
396 present on LB plates supplemented with FeCl<sub>3</sub> (**S1 Fig.**). Thus, excess iron was  
397 responsible for the red phenotype.

398         *B. subtilis* and many other microorganisms produce and secrete the iron chelator  
399 pulcherriminic acid, which binds to free ferric iron to form the insoluble pigment  
400 pulcherrimin [14,15,32] (**Fig. 6A**). We hypothesized that the red phenotype was caused  
401 by the production of pulcherrimin. Therefore, we made mutations in one the two key  
402 pulcherrimin biosynthetic genes (*yvmC*) in the WT and *scoC::erm* backgrounds. After  
403 growth in liquid and on solid media, the red phenotype in the mutants lacking *yvmC* was  
404 absent, indicating pulcherrimin is responsible for the red phenotype in both the WT and  
405 *scoC::erm* backgrounds (**Fig. 1**). Additionally, mass spectrometry analysis of cyclo(L-

406 leucine-L-leucine) (cLL), a pulcherriminic acid precursor synthesized by the cyclization of  
407 tRNA-charged leucine by YvmC, showed that mutants lacking *yvmC* no longer have  
408 detectable cLL (**S2 Fig.**). Further, complementing the *scoC::erm* by ectopically expressing  
409 *scoC* from its native promoter causes the red phenotype to disappear (**S3 Fig.**). Together,  
410 our results indicate that ScoC negatively controls pulcherriminic acid production, in turn  
411 resulting in increased extracellular pulcherrimin and the red color in TSS media.

### 412 **Multiple Systems Control Pulcherrimin Production in *B. subtilis*.**

413 Past studies have identified AbrB, another TSR, as a regulator of pulcherrimin  
414 production in *B. subtilis* and *Bacillus licheniformis* [9,15]. We therefore generated an *abrB*  
415 disruption strain (*abrB::kan*) and assessed pigment formation after overnight growth. Like  
416 *scoC::erm*, the liquid media turned slightly pink relative to WT. On solid media, *abrB::kan*  
417 appeared wrinkly and was less red than *scoC::erm* and more red than WT (**Fig. 1**). The  
418 wrinkly phenotype of *abrB::kan* colonies is due to its role in negatively regulating biofilm  
419 formation [33].

420 Many bacteria that encode the pulcherriminic acid biosynthesis genes also encode  
421 the negative regulator *pchR* which inhibits expression of the biosynthesis operon [12]. In  
422 *B. subtilis*, mutants lacking *pchR* appear red in liquid culture after overnight growth in  
423 minimal media (MS media) [13]. Indeed, deletion of *pchR* ( $\Delta pchR$ ) resulted in a more  
424 intense red coloring of the liquid and solid TSS media compared to WT and the other  
425 single mutants (**Fig. 1**). Combining the mutations in the same background, resulting in  
426 three double-mutants and one triple mutant, results in a color intensity higher than any  
427 single mutant alone (**Fig. 1**). However, whether there are differences in the amount, or  
428 even the rate at which pulcherrimin produced, is not easily determined with qualitative

429 comparisons, necessitating a quantitative assessment of pulcherrimin production during  
430 a growth curve (see below).

431 **ScoC, AbrB, and PchR Control the Timing, Rate, and Amount of Pulcherrimin**  
432 **Produced in Liquid Cultures.**

433 Iron bound pulcherriminic acid (pulcherrimin) is water-insoluble at neutral pH and  
434 can be sedimented with cells through centrifugation and solubilized in a basic solution (2  
435 mM NaOH). In this solution, pulcherrimin can be analyzed spectrophotometrically with  
436 peak absorbances at 245, 285, and 410 nm [16,34]. Therefore, the amount of  
437 pulcherrimin produced in a culture growing over time can be determined by measuring  
438 the absorbance at 410 nm ( $A_{410}$ ) from alkali-solubilized cell pellets. We were interested in  
439 how pulcherrimin production changed as cells transitioned from exponential growth to  
440 stationary phase. Therefore, we measured the absorbance at 410 nm ( $A_{410}$ ) in the WT  
441 background and found that it rose steadily throughout the growth curve, plateauing at  
442 0.10 after 18 hours post transition into stationary phase (**Fig. 2A**). Interestingly, the  $A_{410}$   
443 in the *yvmC::erm* background, which lacks an enzyme necessary for the pulcherrimin  
444 precursor cLL, is indistinguishable from WT (**S2 Fig., Fig. 2A**). These data demonstrate  
445 pulcherrimin production in the WT background grown in liquid TSS culture is below the  
446 limit of detection for this assay and that the  $A_{410}$  in WT and *yvmC::erm* represents the  
447 background absorbance.

448 We repeated this experiment with all strains and analyzed the data using a growth  
449 model to estimate the start time, the duration, the rate, and the maximum amount of  
450 pulcherrimin produced (**Fig. 2AB**). Genes controlled by TSRs tend to have low expression  
451 during exponential phase and higher expression as cells transition into stationary phase

452 [2,10,31,35–37]. We hypothesized that the effect of *scoC* and *abrB* disruption would  
453 cause increased pulcherrimin production as cells transition into stationary phase while  
454 cells without *pchR* would have higher pulcherrimin production during exponential phase.  
455 Compared to any single mutant,  $\Delta pchR$  had the earliest production start time while  
456 *abrB::erm* began pulcherrimin production just prior to the start of the transition phase (**Fig.**  
457 **2A, Bi**). The maximum production rate and duration of pulcherrimin production were  
458 similar across all single mutants while  $\Delta pchR$  had the highest maximum  $A_{410}$  (**Fig 2Bi-iv**).  
459 The data from the single mutants suggests *pchR* is a potent repressor of pulcherrimin  
460 production, especially during exponential phase while *scoC* and *abrB* contribute to  
461 repress production during late exponential through early stationary phase.

462 We next were interested in how combining mutations to generate double and triple  
463 mutants affected pulcherrimin production parameters. When comparing against the single  
464 mutants, combining *scoC::erm* and *abrB::kan* resulted in a production start time and  
465 production duration comparable to the single *scoC* disruption (**Fig. 2Bi-ii**). However, the  
466 *scoC::erm abrB::kan* background had an increased pulcherrimin production rate and a  
467 maximum  $A_{410}$  much higher than the single mutants, demonstrating positive epistasis  
468 (**Fig. 2Biii-iv, S4 Fig**). Introducing *scoC::erm* or *abrB::kan* into the  $\Delta pchR$  background  
469 generated strains with production start times and pulcherrimin production durations  
470 similar to  $\Delta pchR$  (**Fig. 2Bi**). While the maximum production rate was higher in  $\Delta pchR$   
471 *scoC::erm* than  $\Delta pchR abrB::kan$ , the maximum  $A_{410}$  were similar (**Fig. 2Biii-iv**). This can  
472 be reconciled by the fact that  $\Delta pchR abrB::kan$  has a longer duration of pulcherrimin  
473 production than  $\Delta pchR scoC::erm$  (**Fig. 2Bii**). In the triple mutant background,  
474 pulcherrimin production began at the first sampled timepoint, six hours before the

475 transition into stationary phase, demonstrating all transcription factors contribute to  
476 inhibiting expression during exponential phase (**Fig. 2A, Bi**). The triple mutant had the  
477 longest duration of pulcherrimin production of all mutants tested while the maximum  
478 production rate was lower than most double mutants and similar to all single mutants.  
479 Despite the lower production rate, the maximum  $A_{410}$  was similar to or higher than all  
480 double mutants, likely because of the extended production period (**Fig. 2Bii-iv**). Taken  
481 together, the results indicate multiple transcription factors control the rate, duration, and  
482 maximum amount of pulcherrimin produced and demonstrate an integration of multiple  
483 regulatory systems on an energetically costly phenotype.

#### 484 **The *yvmC* Promoter is Upregulated in the Absence of *ScoC*, *AbrB*, and *PchR*.**

485 As transcription factors, we hypothesized the main role of *ScoC*, *AbrB*, and *PchR*  
486 in controlling pulcherrimin formation likely involves regulating promoter activity. We  
487 therefore fused the promoter for *yvmC* ( $P_{yvmC}$ ) to GFP and measured single-cell  
488 fluorescence via flow cytometry during early exponential phase (approximately 3 hours  
489 before T0). 69.8% (+/- 9.87%) of the WT population were GFP positive compared to a  
490 no GFP control (**Fig. 3A**). The percent positive population of cells in the *scoC::erm* and  
491 *abrB::kan* backgrounds were greater than WT. Further, the wider distribution of  
492 fluorescence intensities indicate a broader range of expression levels within the  
493 population compared to WT. We found a proportional relationship between maximum  $A_{410}$   
494 values and reporter expression for most strains (**Fig. 2Biv, Fig. 3**). Additionally, mutants  
495 with higher reporter activity tend to have more narrow fluorescence distributions (**Fig. 3**).  
496 After many attempts, we were unable to generate a strain harboring the reporter in the  
497 *scoC::erm abrB::kan* double mutant background. Indeed, mutants of *scoC* and *abrB* have

498 decreased expression of the competence regulator *comK* and have decreased  
499 competence compared to WT [7,38]. Together, our results demonstrate PchR, ScoC, and  
500 AbrB work to inhibit expression of the pulcherrimin biosynthesis genes *yvmC* and *cypX*  
501 and that increased promoter expression results in increased pulcherrimin production.

## 502 **Analysis of Transcription Factor Binding at the *yvmC* Promoter.**

503 Randazzo and coworkers aligned promoter regions of PchR regulated genes and  
504 identified a 14-bp consensus sequence termed the PchR-box [13]. To validate their in  
505 silico consensus motif, we utilized fluorescent DNase I footprinting assays followed by  
506 differential peak height analysis to identify the PchR binding site in vitro. PchR  
507 demonstrated a protected region from +6 to +28 relative to the transcriptional start site  
508 (determined by [39]), which overlaps with the previously identified PchR-box (**Fig. 4Ai-ii,**  
509 **[13]**). We repeated this experiment with purified AbrB and ScoC. We found that AbrB had  
510 a broad protection area encapsulating -30 to approximately +60 bp relative to the  
511 transcriptional start site (**Fig. 4B**). **While broader than PchR, the protection region of**  
512 **AbrB is consistent with earlier reports of AbrB-DNA interactions [40]**. Interestingly,  
513 attempts at DNase I footprinting analysis with ScoC and the *yvmC* promoter were  
514 unsuccessful, with no apparent difference in peak heights between samples with and  
515 without protein (**S5A Fig.**). During optimization experiments, we found that ScoC could  
516 bind to the *yvmC* promoter when the non-specific competitor poly dI-dC was used, rather  
517 than the polyanionic compound heparin used in experiments with PchR and AbrB. We  
518 therefore analyzed the DNase I footprint with ScoC using poly dI-dC as a non-specific  
519 competitor and observed a broad protection area from approximately -10 to + 60 relative  
520 to the transcriptional start site (**Fig. 4C**).

521           The footprint data indicated all proteins interacted with the *yvmC* promoter  
522 downstream of the putative SigA binding site (**Fig. 6B**). We therefore generated a mutant  
523 probe where 59 base pairs, from -14 to +45 bp, were deleted ( $\Delta 59$ ) and assessed DNA  
524 binding in vitro by electrophoretic mobility shift assays (EMSA) using the WT and  $\Delta 59$   
525 probes. PchR exhibited the most canonical behavior of the transcription factors,  
526 demonstrating discrete band formation as protein concentration increased (**Fig. 5A**). At  
527 the highest concentration tested, PchR formed a second DNA-bound species that  
528 migrated slower than the other band formed at lower concentrations, suggesting an  
529 additional, low-affinity site may be present in the promoter (**Fig. 5A**). However, DNase I  
530 footprinting analysis identified only one area of protection, suggesting the slow-migrating  
531 complex may be caused by non-specific interactions between PchR and DNA at the high  
532 protein concentration (**Fig. 4A**). Indeed, when using the  $\Delta 59$  probe, which lacks the region  
533 recognized by PchR, there is a faint shift at the highest PchR concentration (**Fig. 5B**).  
534 This suggests that high PchR concentrations can interact with the *yvmC* promoter non-  
535 specifically but demonstrates specific binding at lower concentrations. For AbrB, the  
536 intensity of the unbound probe decreased as protein concentration increased, indicating  
537 that DNA binding is occurring. However, the lack of discrete bands indicate the AbrB-  
538 *PyvmC* interaction likely represent a fast off-rate (**Fig. 5A**). Additionally, protein binding  
539 was not observed in experiments using the  $\Delta 59$  probe (**Fig. 5Bi**). ScoC had smear shifts  
540 at concentrations greater than 250 nM with a band present at 1000 nM (**Fig. 5A**).  
541 Interestingly, a band was also present at 1000 nM when using the  $\Delta 59$  probe but not at  
542 250 or 500 nM, suggesting binding at 1000 nM occurs non-specifically (**Fig. 5B**). Previous  
543 studies of in vitro ScoC-DNA interactions found that ScoC binds to DNA non-specifically



544 at concentrations greater than 400 nM and the DNase I footprint size is around 14-25 bps  
545 [30]. The fact that ScoC bound to the WT probe but not the  $\Delta 59$  probe indicates specificity,  
546 but it is apparent that the ScoC-*yvmC* interaction likely has a fast off-rate as suggested  
547 with AbrB. Nonetheless, the results indicate the PchR and AbrB, collectively, act as road-  
548 blocks to RNAP progression at the *yvmC* promoter while the role of ScoC appears to  
549 involve weak direct regulation and may also have indirect regulation through another  
550 factor that ScoC modulates. Taken together, the presence of the three repressors is  
551 necessary to limit the production of pulcherrimin providing mechanistic insight into the  
552 regulatory network of pulcherrimin production in bacteria.

### 553 **Discussion**

554 In *B. subtilis*, seemingly redundant regulatory pathways are abundant. In this  
555 study, we uncover the layered negative regulation of the iron chelator pulcherrimin by two  
556 discrete regulatory systems. We demonstrate that these systems work together to inhibit  
557 the biosynthetic pathway of an energetically costly and potentially growth limiting  
558 metabolite. While expression patterns of *yvmC*-GFP promoter fusion closely resembled  
559 the pattern of pulcherrimin production, the reporter in the *scoC::erm* and *abrB::kan*  
560 background displayed broad distributions of promoter expression, suggesting the TSRs  
561 influence heterogeneity in pulcherrimin producing cells. Only in the absence of all three  
562 transcription factors is *yvmC* gene expression fully relieved and pulcherrimin is produced  
563 throughout exponential phase. Our biochemical analysis shows the regulator of the  
564 pulcherrimin biosynthesis operon and the transition state regulators ScoC and AbrB bind  
565 to the *yvmC* promoter with differing apparent off-rates. Together, our results indicate

566 pulcherrimin regulation in *Bacillus subtilis* is under tight regulation and repressed during  
567 exponential growth by two distinct regulatory systems.

568         The transition state regulators ScoC and AbrB have been subject to much research  
569 for their roles in diverse aspects of *Bacillus* physiology. The absence of these regulators  
570 modifies sporulation, competence, protease production, and biofilm formation among  
571 many other phenotypes [7,10,35,37,41–44]. Microarray analysis of the effect of *scoC* on  
572 global gene expression was carried out from cells sampled at different points in the growth  
573 cycle in complex media [7]. While hundreds of genes were found to be differentially  
574 regulated in the  $\Delta$ *scoC* background, expression of genes involved in pulcherrimin  
575 biosynthesis were not identified as significantly different from the WT background [7].  
576 This could be due to the rich, complex media used during the experiment, as *B. subtilis*  
577 grown in media with certain amino acids present have lower levels of *scoC* expression  
578 compared to media without amino acids [10,30]. In rich media, the GTP/amino acid-  
579 sensing transcriptional regulator CodY is active and negatively regulates *scoC* expression  
580 [10,30,45]. Under the conditions used for experiments here, the lack of amino acids as a  
581 nitrogen source means CodY is mostly in the inactive state and *scoC* expression is  
582 elevated. Elevated *scoC* could explain how *yvmC* gene expression and pulcherrimin  
583 production is near background levels in WT cells (**Fig. 2 and 3**).

584         The major extracellular proteases AprE and NprE are transcriptionally regulated  
585 by ScoC and AbrB [10]. Promoter expression of *aprE* and *nprE* in TSS media is elevated  
586 above WT in  $\Delta$ *scoC* and  $\Delta$ *abrB* but is similar between the two mutants. Expression  
587 increases beyond expected when *scoC* and *abrB* mutations are combined, similar to the  
588 effect size observed in pulcherrimin production (**Fig. 2, [10]**). While *abrB* has been

589 described as a negative regulator of *scoC* expression, experiments in TSS media found  
590 no effect of an *abrB* mutant on *scoC* promoter expression [2,30]. Thus, the effect of the  
591 double *scoC abrB* mutant on *aprE* and *nprE* expression was attributed to the lack of direct  
592 regulation by CodY, which is inactive in TSS media without amino acid supplementation  
593 [10]. The promoter region of *yvmC* does not have a CodY binding site nor is there  
594 evidence CodY binds to the *yvmC* promoter in vivo [10,30,45]. Therefore, the effect of  
595 CodY on pulcherrimin production likely occurs indirectly through regulation of ScoC,  
596 similar to regulation of the peptide transporter gene *dtpT* [30].

597 In addition to evidence that AbrB directly controls *yvmC* expression in *B. subtilis*,  
598 AbrB was also identified as a direct regulator of pulcherrimin biosynthesis in *B.*  
599 *licheniformis* [9,11,15]. Interestingly, the *abrB* deletion had a larger effect on maximum  
600 pulcherrimin production in *B. licheniformis* than in *B. subtilis*, indicating that despite similar  
601 regulatory components, their effects appear species specific [15]. Further, the homolog  
602 for *pchR* is not located adjacent to the pulcherrimin biosynthesis gene cassette like *B.*  
603 *subtilis* (**Fig. 6B**). A neighboring MarR-family transcription factor YvnA was also identified  
604 as a regulator of pulcherrimin biosynthesis in *B. licheniformis*, where it bound directly to  
605 the intergenic region between *yvmA* and *yvmC* [15]. One possibility is that the different  
606 genetic organizations of the pulcherrimin biosynthetic gene cassette may necessitate  
607 alternative forms of regulation, thus explaining the difference between *B. licheniformis*  
608 and *B. subtilis*.

609 In *B. subtilis*, the *pchR* gene is located adjacent to *yvmA* and divergently  
610 transcribed from *yvmC-cypX* (**Fig. 6B**) and binds to a consensus motif (PchR-box)  
611 upstream of *yvmC*. Our footprinting analysis identified the same region protected from

612 DNase treatment, validating the predicted motif [13]. MarR family transcription factors  
613 commonly bind to small ligands which alter their DNA binding capabilities [46]. ZitR, a  
614 Zn<sup>2+</sup>-binding MarR transcription factor from *Lactococcus lactis*, is the template for PchR  
615 homology modeling by Phyre2 [47]. In the cytosol, iron species tend to be in the reduced  
616 Fe<sup>2+</sup> state, thus it is tempting to hypothesize that ferrous iron is the ligand to inhibit PchR  
617 repression [48]. However, several lines of evidence indicate iron is not directly involved  
618 in pulcherriminic acid production. For example, *B. subtilis* grown in minimal media  
619 supplemented with very low iron (0.0001 w/v% ferric ammonium citrate), produced no  
620 pigment after overnight growth [49]. Yet, pigment formed with peak absorbance at 410  
621 nm after supplementation of ferric ammonium citrate crystals directly to culture, indicating  
622 pulcherriminic acid is produced despite the low levels of iron in the growth medium [49].  
623 Further, work from Angelini and coworkers demonstrated the *yvmC* promoter activity is  
624 not responsive to iron supplementation [50]. Thus, the ligand for PchR, if it exists, has  
625 yet to be determined but would provide insight into conditions that favor pulcherrimin  
626 production.

627       Why *B. subtilis* and other organisms produce pulcherrimin is a topic of interest.  
628 Recent studies found that *B. subtilis* in biofilms produce pulcherrimin as a form of niche  
629 protection by creating a zone of iron limitation around the biofilm [12]. Other groups found  
630 that pulcherrimin production increased resistance to reactive oxygen species (ROS),  
631 likely by decreasing the amount of iron available for Fenton reactions [50,51]. The role of  
632 an antioxidant is interesting given that stationary phase cells tend to be more tolerant to  
633 hydrogen peroxide than cells in exponential phase independent of prior exposure to ROS  
634 [52]. Additionally, production of the cytosolic mini-ferritin MrgA is increased as cells

635 transition into stationary phase in a mechanism independent of TSRs [53]. As a Dps  
636 homolog, MrgA is predicted to sequester iron and enzymatically oxidize Fe(II) to the  
637 insoluble and less reactive Fe(III) [54]. Thus, control of pulcherrimin production by TSRs  
638 agrees with a model wherein intracellular and extracellular iron is sequestered as cells  
639 enter stationary phase, limiting proliferation of reactive oxygen species.

640

#### 641 **Acknowledgements**

642 We would like to thank members of the Simmons lab for helpful discussions during the  
643 progression of this work, the Michigan State University Mass Spectrometry and Metabolomics  
644 Core for quantitative measurements of intracellular cyclo-(L-leucine-L-leucine), and J.M.  
645 Fernandez for constructing the light box used to image agar plates. This work was supported by  
646 grant 1R35GM131772 from the National Institutes of Health to LAS and by an NSF PRFB award  
647 (2010735).

## 648 **References**

- 649 1. Zeigler DR. The Bacillus Genetic Stock Center/*Bacillus subtilis*. 1st ed. In: Jarret  
650 RL, McCluskey K, editors. The Biological Resources of Model Organisms. 1st ed.  
651 Boca Raton, Florida : CRC Press, [2019]: CRC Press; 2019. pp. 35–53.  
652 doi:10.1201/9781315100999-3
- 653 2. Perego M, Hoch JA. Sequence analysis and regulation of the *hpr* locus, a  
654 regulatory gene for protease production and sporulation in *Bacillus subtilis*. J  
655 Bacteriol. 1988;170: 2560–2567. doi:10.1128/jb.170.6.2560-2567.1988
- 656 3. Strauch MA, Hoch JA. Biology of Bacilli. Butterworth; 1991. pp. 105–121.
- 657 4. Strauch MA, Hoch JA. Transition-state regulators: sentinels of *Bacillus subtilis* post-  
658 exponential gene expression. Mol Microbiol. 1993;7: 337–342. doi:10.1111/j.1365-  
659 2958.1993.tb01125.x
- 660 5. Higerd TB, Hoch JA, Spizizen J. Hyperprotease-Producing Mutants of *Bacillus*  
661 *subtilis*. J Bacteriol. 1972;112: 1026–1028. doi:10.1128/jb.112.2.1026-1028.1972
- 662 6. Kallio PT, Fagelson JE, Strauch MA. The Transition State Regulator Hpr of *Bacillus*  
663 *subtilis* Is a DNA-binding Protein. The Journal of Biological Chemistry. 1991;226:  
664 13411–13417.
- 665 7. Caldwell R, Sapolsky R, Weyler W, Maile RR, Causey SC, Ferrari E. Correlation  
666 between *Bacillus subtilis* *scoC* Phenotype and Gene Expression Determined Using  
667 Microarrays for Transcriptome Analysis. Journal of Bacteriology. 2001;183: 7329–  
668 7340. doi:10.1128/JB.183.24.7329-7340.2001
- 669 8. Coles M, Djuranovic S, Söding J, Frickey T, Koretke K, Truffault V, et al. AbrB-like  
670 Transcription Factors Assume a Swapped Hairpin Fold that Is Evolutionarily  
671 Related to Double-Psi  $\beta$  Barrels. Structure. 2005;13: 919–928.  
672 doi:10.1016/j.str.2005.03.017
- 673 9. Chumsakul O, Takahashi H, Oshima T, Hishimoto T, Kanaya S, Ogasawara N, et al.  
674 Genome-wide binding profiles of the *Bacillus subtilis* transition state regulator AbrB  
675 and its homolog Abh reveals their interactive role in transcriptional regulation.  
676 Nucleic Acids Research. 2011;39: 414–428. doi:10.1093/nar/gkq780
- 677 10. Barbieri G, Albertini AM, Ferrari E, Sonenshein AL, Belitsky BR. Interplay of CodY  
678 and ScoC in the Regulation of Major Extracellular Protease Genes of *Bacillus*  
679 *subtilis*. Henkin TM, editor. Journal of Bacteriology. 2016;198: 907–920.  
680 doi:10.1128/JB.00894-15
- 681 11. Chumsakul O, Nakamura K, Kurata T, Sakamoto T, Hobman JL, Ogasawara N, et  
682 al. High-Resolution Mapping of In vivo Genomic Transcription Factor Binding Sites  
683 Using In situ DNase I Footprinting and ChIP-seq. DNA Research. 2013;20: 325–  
684 338. doi:10.1093/dnares/dst013

- 685 12. Arnaouteli S, Matoz-Fernandez DA, Porter M, Kalamara M, Abbott J, MacPhee CE,  
686 et al. Pulcherrimin formation controls growth arrest of the *Bacillus subtilis* biofilm.  
687 Proc Natl Acad Sci USA. 2019;116: 13553–13562. doi:10.1073/pnas.1903982116
- 688 13. Randazzo P, Aubert-Frambourg A, Guillot A, Auger S. The MarR-like protein PchR  
689 (YvmB) regulates expression of genes involved in pulcherriminic acid biosynthesis  
690 and in the initiation of sporulation in *Bacillus subtilis*. BMC Microbiol. 2016;16: 190.  
691 doi:10.1186/s12866-016-0807-3
- 692 14. Krause DJ, Kominek J, Oplente DA, Shen X-X, Zhou X, Langdon QK, et al.  
693 Functional and evolutionary characterization of a secondary metabolite gene  
694 cluster in budding yeasts. Proc Natl Acad Sci USA. 2018;115: 11030–11035.  
695 doi:10.1073/pnas.1806268115
- 696 15. Wang D, Zhan Y, Cai D, Li X, Wang Q, Chen S. Regulation of the Synthesis and  
697 Secretion of the Iron Chelator Cyclodipeptide Pulcherriminic Acid in *Bacillus*  
698 *licheniformis*. Drake HL, editor. Appl Environ Microbiol. 2018;84: e00262-18.  
699 doi:10.1128/AEM.00262-18
- 700 16. Kluyver AJ, Van Der Walt JP, Van Triet AJ. Pulcherrimin, The Pigment of *Candida*  
701 *Pulcherrima*. Proc Natl Acad Sci USA. 1953;39: 583–593.  
702 doi:10.1073/pnas.39.7.583
- 703 17. Konkol MA, Blair KM, Kearns DB. Plasmid-Encoded ComI Inhibits Competence in  
704 the Ancestral 3610 Strain of *Bacillus subtilis*. Journal of Bacteriology. 2013;195:  
705 4085–4093. doi:10.1128/JB.00696-13
- 706 18. Koo B-M, Kritikos G, Farelli JD, Todor H, Tong K, Kimsey H, et al. Construction and  
707 Analysis of Two Genome-Scale Deletion Libraries for *Bacillus subtilis*. Cell  
708 Systems. 2017;4: 291-305.e7. doi:10.1016/j.cels.2016.12.013
- 709 19. Routh S, Acharyya A, Dhar R. A two-step PCR assembly for construction of gene  
710 variants across large mutational distances. Biology Methods and Protocols. 2021;6:  
711 bpab007. doi:10.1093/biomethods/bpab007
- 712 20. Trauth S, Bischofs IB. Ectopic Integration Vectors for Generating Fluorescent  
713 Promoter Fusions in *Bacillus subtilis* with Minimal Dark Noise. Scheffers D-J, editor.  
714 PLoS ONE. 2014;9: e98360. doi:10.1371/journal.pone.0098360
- 715 21. Smith P, Schuster M. Inexpensive Apparatus for High-Quality Imaging of Microbial  
716 Growth on Agar Plates. Front Microbiol. 2021;12: 689476.  
717 doi:10.3389/fmicb.2021.689476
- 718 22. Pisithkul T, Schroeder JW, Trujillo EA, Yeesin P, Stevenson DM, Chaiamarit T, et al.  
719 Metabolic Remodeling during Biofilm Development of *Bacillus subtilis*. Ghigo J-M,  
720 Greenberg EP, editors. mBio. 2019;10: e00623-19. doi:10.1128/mBio.00623-19



- 721 23. Hall BG, Acar H, Nandipati A, Barlow M. Growth Rates Made Easy. *Molecular*  
722 *Biology and Evolution*. 2014;31: 232–238. doi:10.1093/molbev/mst187
- 723 24. Baier F, Gauye F, Perez-Carrasco R, Payne JL, Schaerli Y. Environment-dependent  
724 epistasis increases phenotypic diversity in gene regulatory networks. *SCIENCE*  
725 *ADVANCES*. 2023.
- 726 25. Nye TM, van Gijtenbeek LA, Stevens AG, Schroeder JW, Randall JR, Matthews  
727 LA, et al. Methyltransferase DnmA is responsible for genome-wide N6-  
728 methyladenosine modifications at non-palindromic recognition sites in *Bacillus*  
729 *subtilis*. *Nucleic Acids Research*. 2020;48: 5332–5348. doi:10.1093/nar/gkaa266
- 730 26. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al.  
731 Fiji: an open-source platform for biological-image analysis. *Nature Methods*.  
732 2012;9: 676–682. doi:10.1038/nmeth.2019
- 733 27. Covarrubias-Pazaran G, Diaz-Garcia L, Schlautman B, Salazar W, Zalapa J.  
734 Fragman: an R package for fragment analysis. *BMC Genet*. 2016;17: 62.  
735 doi:10.1186/s12863-016-0365-6
- 736 28. Grinberg S. findPeaks. Available: <https://github.com/stas-g/findPeaks>
- 737 29. Davlieva M, Shi Y, Leonard PG, Johnson TA, Zianni MR, Arias CA, et al. A variable  
738 DNA recognition site organization establishes the LiaR-mediated cell envelope  
739 stress response of enterococci to daptomycin. *Nucleic Acids Research*. 2015;43:  
740 4758–4773. doi:10.1093/nar/gkv321
- 741 30. Belitsky BR, Barbieri G, Albertini AM, Ferrari E, Strauch MA, Sonenshein AL.  
742 Interactive regulation by the *Bacillus subtilis* global regulators CodY and ScoC.  
743 *Molecular Microbiology*. 2015;97: 698–716. doi:10.1111/mmi.13056
- 744 31. Ogura M, Matsuzawa A, Yoshikawa H, Tanaka T. *Bacillus subtilis* SalA (YbaL)  
745 Negatively Regulates Expression of *scoC*, Which Encodes the Repressor for the  
746 Alkaline Exoprotease Gene, *aprE*. *Journal of Bacteriology*. 2004;186: 3056–3064.  
747 doi:10.1128/JB.186.10.3056-3064.2004
- 748 32. Uffen RL, Canale-Parola E. Synthesis of Pulcherriminic Acid by *Bacillus subtilis*. *J*  
749 *Bacteriol*. 1972;111: 86–93. doi:10.1128/jb.111.1.86-93.1972
- 750 33. Hamon MA, Lazazzera BA. The sporulation transcription factor Spo0A is required  
751 for biofilm development in *Bacillus subtilis*. *Molecular Microbiology*. 2001;42: 1199–  
752 1209. doi:10.1046/j.1365-2958.2001.02709.x
- 753 34. Canale-Parola E. A red pigment produced by aerobic sporeforming bacteria. *Archiv*  
754 *für Mikrobiologie*. 1963; 414–417.



- 755 35. Kaushal B, Paul S, Hulett FM. Direct Regulation of *Bacillus subtilis* *phoPR*  
756 Transcription by Transition State Regulator ScoC. *Journal of Bacteriology*.  
757 2010;192: 3103–3113. doi:10.1128/JB.00089-10
- 758 36. Kodgire P, Rao KK. *hag* expression in *Bacillus subtilis* is both negatively and  
759 positively regulated by ScoC. *Microbiology*. 2009;155: 142–149.  
760 doi:10.1099/mic.0.021899-0
- 761 37. Koide A, Perego M, Hoch JA. ScoC Regulates Peptide Transport and Sporulation  
762 Initiation in *Bacillus subtilis*. 1999;181: 4.
- 763 38. Hahn J, Luttinger A, Dubnau D. Regulatory inputs for the synthesis of ComK, the  
764 competence transcription factor of *Bacillus subtilis*. *Molecular Microbiology*.  
765 1996;21: 763–775. doi:10.1046/j.1365-2958.1996.371407.x
- 766 39. Zhu B, Stülke J. SubtiWiki in 2018: from genes and proteins to functional network  
767 annotation of the model organism *Bacillus subtilis*. *Nucleic Acids Research*.  
768 2018;46: D743–D748. doi:10.1093/nar/gkx908
- 769 40. Strauch MA, Spiegelman GB, Perego M, Johnson WC, Burbulys D, Hoch JA. The  
770 transition state transcription regulator *abrB* of *Bacillus subtilis* is a DNA binding  
771 protein. *The EMBO Journal*. 1989;8: 1615–1621. doi:10.1002/j.1460-  
772 2075.1989.tb03546.x
- 773 41. Bobay BG, Benson L, Naylor S, Feeney B, Clark AC, Goshe MB, et al. Evaluation  
774 of the DNA Binding Tendencies of the Transition State Regulator AbrB.  
775 *Biochemistry*. 2004;43: 16106–16118. doi:10.1021/bi048399h
- 776 42. Bochmann SM, Spieß T, Kötter P, Entian K-D. Synthesis and Succinylation of  
777 Subtilin-Like Lantibiotics Are Strongly Influenced by Glucose and Transition State  
778 Regulator AbrB. Drake HL, editor. *Appl Environ Microbiol*. 2015;81: 614–622.  
779 doi:10.1128/AEM.02579-14
- 780 43. Hamoen LW, Kausche D, Marahiel MA, Sinderen D, Venema G, Serror P. The  
781 *Bacillus subtilis* transition state regulator AbrB binds to the –35 promoter region of  
782 *comK*. *FEMS Microbiology Letters*. 2003;218: 299–304. doi:10.1111/j.1574-  
783 6968.2003.tb11532.x
- 784 44. Inaoka T, Wang G, Ochi K. ScoC Regulates Bacilysin Production at the  
785 Transcription Level in *Bacillus subtilis*. *Journal of Bacteriology*. 2009;191: 7367–  
786 7371. doi:10.1128/JB.01081-09
- 787 45. Belitsky BR, Sonenshein AL. Genome-wide identification of *Bacillus subtilis* CodY-  
788 binding sites at single-nucleotide resolution. *Proc Natl Acad Sci USA*. 2013;110:  
789 7026–7031. doi:10.1073/pnas.1300428110

- 790 46. Deochand DK, Grove A. MarR family transcription factors: dynamic variations on a  
791 common scaffold. *Critical Reviews in Biochemistry and Molecular Biology*. 2017;52:  
792 595–613. doi:10.1080/10409238.2017.1344612
- 793 47. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal  
794 for protein modeling, prediction and analysis. *Nat Protoc*. 2015;10: 845–858.  
795 doi:10.1038/nprot.2015.053
- 796 48. Helmann JD. Specificity of Metal Sensing: Iron and Manganese Homeostasis in  
797 *Bacillus subtilis*. *Journal of Biological Chemistry*. 2014;289: 28112–28120.  
798 doi:10.1074/jbc.R114.587071
- 799 49. Kupfer DG, Uffen RL, Canale-Parola E. The Role of Iron and Molecular Oxygen in  
800 Puleherrimin Synthesis by Bacteria. *Archiv für Mikrobiologie*. 1967; 9–21.
- 801 50. Angelini LL, Dos Santos RAC, Fox G, Paruthiyil S, Gozzi K, Shemesh M, et al.  
802 Pulcherrimin protects *Bacillus subtilis* against oxidative stress during biofilm  
803 development. *npj Biofilms Microbiomes*. 2023;9: 50. doi:10.1038/s41522-023-  
804 00418-z
- 805 51. Charron-Lamoureux V, Haroune L, Pomerleau M, Hall L, Orban F, Leroux J, et al.  
806 Pulcherriminic acid modulates iron availability and protects against oxidative stress  
807 during microbial interactions. *Nat Commun*. 2023;14: 2536. doi:10.1038/s41467-  
808 023-38222-0
- 809 52. Dowds BCA, Hoch JA. Regulation of the oxidative stress response by the *hpr* gene  
810 in *Bacillus subtilis*. *Journal of General Microbiology*. 1991;137: 1121–1125.  
811 doi:10.1099/00221287-137-5-1121
- 812 53. Chen L, James LP, Helmann JD. Metalloregulation in *Bacillus subtilis*: isolation and  
813 characterization of two genes differentially repressed by metal ions. *J Bacteriol*.  
814 1993;175: 5428–5437. doi:10.1128/jb.175.17.5428-5437.1993
- 815 54. Orban K, Finkel SE. Dps Is a Universally Conserved Dual-Action DNA-Binding and  
816 Ferritin Protein. Maupin-Furlow JA, editor. *J Bacteriol*. 2022;204: e00036-22.  
817 doi:10.1128/jb.00036-22

818  
819

## 820 **Supporting Information**

821 **Fig. 1: Pulcherrimin production in liquid (top) and solid (bottom) TSS media.** WT  
822 (DK1042) and isogenic mutants were grown in liquid TSS media or spotted (10  $\mu$ L) onto  
823 solid TSS media and grown overnight at 37°C. The black scale marker corresponds to  
824 5 mm.

825  
826 **Fig. 2: ScoC, ArbB, and PchR Control Timing and Rate of Pulcherrimin Production.**  
827 **A)** Pulcherrimin production was measured as a function of growth phase, where T<sub>0</sub> marks  
828 the transition from the exponential growth to stationary phase. Each panel represents the  
829 average A<sub>410</sub> for a given strain compared to the A<sub>410</sub> from WT (white squares). Error bars  
830 represent +/- the standard deviation. Lines running through the points are modeled using  
831 the *drm* function from the *drc* package in R (see Methods and Materials). **B)** Pulcherrimin  
832 production parameters as a function of genetic background: *i*) start of pulcherrimin  
833 production time relative to the transition phase of growth (T<sub>0</sub>), *ii*) the duration of  
834 pulcherrimin production, *iii*) the maximum estimated production rate, and *iv*) the maximum  
835 absorbance at 410 nm. For panels *i-iii*, brackets and asterisks indicate significant  
836 comparisons. For panel *iv*, brackets and “ns” indicate non-significant comparisons, where  
837 every other comparison had an adjusted p-value less than 0.05 as determined by T-test  
838 corrected for multiple comparisons with the Bonferroni correction.

839  
840 **Fig. 3: ScoC, PchR, and AbrB Repress the *yvmC* Promoter.** **A)** Histograms  
841 representing fluorescence distribution as a function of cell count. In each panel, the  
842 negative control (grey, WT without GFP) was plotted with the corresponding genotype  
843 harboring a *yvmC* promoter fusion to GFP. Mean percent GFP positive with standard  
844 deviation in parentheses is provided to the right of each plot. Fluorescence was measured  
845 independently for each strain on three separate days with a representative shown. **B)**  
846 Median fluorescence for three separate trials (bar) with each trial median shown (circles).  
847 Error bars represent stand deviation between trials. Asterisks indicate an adjusted p-value  
848 less 0.05 while “ns” indicate non-significant comparisons with WT.

849  
850 **Fig. 4: DNase I Protection Varies Among ScoC, PchR, and AbrB.** Electropherograms  
851 of fluorescent DNase I footprinting analysis of PchR (A), AbrB (B), and ScoC (C) with  
852 fluorescently labeled *yvmC* promoter as a function of estimated nucleotide position.  
853 Fluorescence intensity (RFU, panel *i*) of reactions incubated with (blue) and without  
854 protein (red). Differential peak height (panel *ii*) between reactions with protein and without  
855 protein. Differential peak heights less than zero indicate protection while differential peak  
856 heights greater than zero hypersensitivity.

857  
858 **Fig. 5: ScoC, PchR, and AbrB Bind Near the Core Promoter Region of *yvmC*.**  
859 Electrophoretic mobility shift assays with WT *P<sub>yvmC</sub>* (A) and the  $\Delta$ 59 promoter *P<sub>yvmC $\Delta$ 59</sub>* (B)  
860 with increasing concentrations of purified PchR (left panel), AbrB (middle panel), and  
861 ScoC (right panel). Unshifted bands are marked with unfilled triangles, shifted bands are  
862 marked with filled triangles, and smears are marked with brackets. Proteins were diluted  
863 two-fold and final concentrations are as follows: PchR (15.6 to 250 nM for WT, 125-250

864 nM for  $\Delta 59$ ), AbrB (62.5 to 1000 nM for WT, 500-1000 nM for  $\Delta 59$ ), and ScoC (125 to  
865 1000 nM for WT, 250-1000 nM for  $\Delta 59$ ).

866

867 **Fig. 6: Model of Pulcherrimin Regulation by ScoC, AbrB, and PchR. A)** Pulcherriminic  
868 acid biosynthesis by the cyclization of tRNA-charged leucines to form cyclo(L-leucine-  
869 leucine) and the subsequent oxidation by CypX to form water-soluble pulcherriminic acid.  
870 Pulcherriminic acid is then transported out of the cell by YvmA, where it can form the  
871 insoluble pulcherrimin complex with iron, which forms a red color and has a peak  
872 absorbance at 410 nm. **B)** During exponential growth, PchR, AbrB, and ScoC bind directly  
873 to the *yvmC* promoter to inhibit expression of *yvmC-cypX*. Our data suggests ScoC can  
874 bind to the promoter but does so weakly. Thus, it is possible its mode of regulation may  
875 be direct or indirect through an unidentified transcriptional regulator controlled by ScoC.  
876 In any case, as nutrients become limiting, the transition state regulators become inactive,  
877 relieving repression on the *yvmC* promoter. As a MarR family transcription factor, PchR  
878 activity is likely regulated by a small ligand of which the identity is currently not known.

879

880 **S1 Fig. Iron Supplementation Influences Pulcherrimin Phenotype in WT and**  
881 **isogenic mutants of *Bacillus subtilis*.** 10  $\mu$ L spots of WT and isogenic mutants on  
882 TSS (top) or LB (bottom) supplemented with different concentrations of ferric citrate.  
883 The black scale bar represents 5 mm.

884

885 **S2 Fig. Cyclo-(L-leucine-L-leucine) Detection from WT and *yvmC::erm***  
886 **Backgrounds.** Metabolites were extracted from WT (A) and *yvmC::erm* (B) grown in  
887 liquid culture and were subject to mass spectrometry analysis for cyclo-(L-leucine-L-  
888 leucine), a precursor metabolite for pulcherrimin. The experiment was repeated at least  
889 three times with representative data shown. RT (retention time) and S/N (signal to  
890 noise ratio) for the peak corresponding to cLL are shown in each panel. The S/N ratio  
891 for *yvmC::erm* was under the limit for detection (UD, undetermined).

892

893 **S3 Fig. Complementation of *scoC::erm* Restores WT Pulcherrimin Phenotype.**  
894 Liquid pulcherrimin measurements from WT, *scoC::erm*, and *scoC::erm lacA::p<sub>scoC</sub>-*  
895 *scoC* from late stationary phase cultures grown in TSS medium. Bars represent the  
896 mean  $A_{410}$  from five independent replicates.


897

898 **S4 Fig. Epistasis analysis for estimated maximum production rate ( $\mu_{max}$ , right)**  
899 **and pulcherrimin carrying capacity (K, right).** Epsilon ( $\epsilon$ ), defined as the difference  
900 between the double mutant from the log-additive effects of the corresponding single  
901 mutants (see Methods), plotted for all double and triple mutant strains. Asterisks indicate  
902 significant difference between the mean and 0 using a 1-sample t-test corrected for  
903 multiple comparisons with the Bonferroni correction.

904

905 **S5 Fig. Addition of Heparin Abolishes ScoC-DNA Complexes.** Similar to Fig. 5C  
906 except heparin was added to the reactions. Fluorescent DNase I footprinting (i) and  
907 DFACE analysis with ScoC (ii). In the top panel, red electropherograms represent no  
908 protein while blue electropherograms represent reactions with protein.


909



910

911 Fig. 1: Pulcherrimin production in liquid (top) and solid (bottom) TSS media.

912




913


914 **Fig. 2: ScoC, ArbB, and PchR Control Timing and Rate of Pulcherrimin Production.**

915






916 **Fig. 3: ScoC, PchR, and AbrB Repress the *yvmC* Promoter.**



917

918 **Fig 4: DNase I Protection Varies Among ScoC, PchR, and AbrB.**






919  
920

**Fig. 5: ScoC, PchR, and AbrB Bind Near the Core Promoter Region of *yvmC*.**

921  
922



923

924

**Fig. 6: Model of Pulcherrimin Regulation by ScoC, AbrB, and PchR.**

925

926

927

928

929

930

931

932

933

934

935

936


937

938

939


940

941




942


943 **S1 Fig.:** Iron Supplementation Influences Pulcherrimin Phenotype in WT and isogenic  
944 mutants of *Bacillus subtilis*.



945 **S2 Fig.:** Cyclo-(L-leucine-L-leucine) Detection from WT and *yvmC::erm* Backgrounds.  
946  
947  
948




949 **S3 Fig.:** Complementation of scoC::erm Restores WT Pulcherrimin Phenotype.  
950



951  
952  
953  
954  
955

**S4 Fig.:** Epistasis analysis for estimated maximum production rate ( $\mu_{max}$ , right) and pulcherrimn carrying capacity ( $K$ , right).



956  
957  
958  
959  
960

**S5 Fig.:** Addition of Heparin Abolishes ScoC-DNA Complexes.